Erik Domines - Xbrane Biopharma G Counsel

All Insiders . Sweden . 
Stock . Xbrane Biopharma AB . Stakeholders . Insider . Erik Domines
XBRANE Stock  SEK 0.16  0.01  5.88%   

Insider

Erik Domines is G Counsel of Xbrane Biopharma AB
Age 59
Phone46 7 60 34 67 33
Webhttps://www.xbrane.com

Xbrane Biopharma Management Efficiency

The company has return on total asset (ROA) of (0.1313) % which means that it has lost $0.1313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3703) %, meaning that it generated substantial loss on money invested by shareholders. Xbrane Biopharma's management efficiency ratios could be used to measure how well Xbrane Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.
Xbrane Biopharma AB has accumulated 36.48 M in total debt with debt to equity ratio (D/E) of 48.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Xbrane Biopharma has a current ratio of 1.42, which is within standard range for the sector. Debt can assist Xbrane Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Xbrane Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Xbrane Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Xbrane to invest in growth at high rates of return. When we think about Xbrane Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Emanuel BjrneHansa Biopharma AB
50
Johanna GransVicore Pharma Holding
N/A
Anita BComSaniona AB
55
Charlotta LiljebrisXSpray Pharma AB
59
Sren MScHansa Biopharma AB
58
Janus LarsenSaniona AB
51
Katja MargellHansa Biopharma AB
N/A
Nina CarlenVicore Pharma Holding
N/A
Jorgen DrejerSaniona AB
68
Jessica ShullVicore Pharma Holding
N/A
Mustafa DemirbkerXSpray Pharma AB
N/A
CarlJohan MDVicore Pharma Holding
67
Palle MSSaniona AB
65
Kicki JohanssonVicore Pharma Holding
65
Anne LannerHansa Biopharma AB
54
AnnaKarin EkbergXSpray Pharma AB
57
Elin RosendahlVicore Pharma Holding
N/A
Kerstin HasselgrenXSpray Pharma AB
62
Asa MagnussonVicore Pharma Holding
N/A
Andreas KonarXSpray Pharma AB
74
Karin NielsenSaniona AB
N/A
Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people. Xbrane Biopharma AB (XBRANE) is traded on Stockholm Exchange in Sweden and employs 74 people.

Management Performance

Return On Equity-0.37
Return On Asset-0.13

Xbrane Biopharma Leadership Team

Elected by the shareholders, the Xbrane Biopharma's board of directors comprises two types of representatives: Xbrane Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xbrane. The board's role is to monitor Xbrane Biopharma's management team and ensure that shareholders' interests are well served. Xbrane Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xbrane Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Nina Ivers, Head HR
Maria Edebrink, Head Assurance
Siavash Bashiri, COO, Head of Biosimilars
Dina Jurman, Head of Clinical Affairs
Anette Lindqvist, CFO Relations
Martin mark, Chief Officer
David Vikstrm, Chief Officer
Associate Gier, CoFounder
Samuel Wagner, CoFounder Board
Erik Domines, G Counsel

Xbrane Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xbrane Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.37
Return On Asset-0.13
Operating Margin(4.61) %
Current Valuation2.32 B
Shares Outstanding27.51 M
Shares Owned By Insiders35.23 %
Shares Owned By Institutions22.09 %
Price To Earning(10.92) X
Price To Book7.49 X
Price To Sales75.09 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in Xbrane Stock

Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY